Sign In
Buy PRQR
$1.73
-0.0300 (-1.70%)
At Close: Jul 10, 2026
ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis
10:52am, Saturday, 04'th Jul 2026
ProQR Therapeutics (PRQR) has transitioned its RNA editing platform from preclinical promise to demonstrated human pharmacological activity, notably with AX-0810's Phase 1 target engagement data. PRQR
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
06:35am, Thursday, 25'th Jun 2026
LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives th
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR or the Company), a clinical-stage biotechnology company dedicated to changing li
ProQR Announces First Quarter 2026 Operating and Financial Results
07:00am, Tuesday, 12'th May 2026
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDU
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
11:01am, Thursday, 07'th May 2026
ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
08:00am, Monday, 04'th May 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
08:00am, Thursday, 30'th Apr 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative R
ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter
04:40am, Thursday, 09'th Apr 2026
ProQR Therapeutics (NASDAQ: PRQR) outlined multiple pipeline updates and development priorities during its virtual investor and analyst event, highlighting upcoming clinical readouts for its lead RNA
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
05:26pm, Wednesday, 08'th Apr 2026
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
04:00pm, Wednesday, 08'th Apr 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies ba
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
08:00am, Wednesday, 08'th Apr 2026
ProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR's AI-enabled drug discovery for Axiomer™ ProQR establishes AI Advisory Board with leaders
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
08:00am, Wednesday, 25'th Mar 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript
03:12pm, Wednesday, 18'th Mar 2026
ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
11:16am, Thursday, 12'th Mar 2026
ProQR (PRQR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.1 per share a year ago.
